Search Results

Jiluntai's independently developed HER2-targeted diagnostic new drug has been approved for clinical trials, expected to facilitate precision treatment of breast cancer

Jiluntai Company, a nuclear medicine innovation enterprise invested and incubated by Baiyang Pharmaceutical Group, has recently made important progress. Its independently developed Class 1 chemical radioactive diagnostic new drug —— Technetium [⁹⁹ᵐTc] hydrazinonicotinamide dual-chain Ark peptide injection (⁹⁹ᵐTc‑HP‑Ark2), has received supplementary clinical trial application approval from the National Medical Products Administration (NMPA), which means the product will continue to undergo clinical trials, bringing new hope for precision subtyping and treatment of breast cancer. This product is a radioactive diagnostic agent for SPECT/CT imaging, intended for the differential diagnosis of HER2-positive breast cancer. HER2 is an important prognostic indicator for malignant tumors such as breast cancer...

2026-09-21

Russian Researchers Propose New Method for Preparing Iron-59 Magnetite Nanoparticles, Potentially Advancing Nuclear Medicine Diagnostics and Therapy

Russian researchers have developed a new method for preparing iron-59-labeled magnetite nanoparticles, which is expected to provide a new material preparation pathway for medical applications such as magnetic resonance imaging, single-photon emission computed tomography, and radionuclide therapy. According to reports, researchers from the Vernadsky Institute of Geochemistry and Analytical Chemistry and the Karpov Institute of Physical Chemistry, both under the Russian Academy of Sciences, have proposed synthesizing iron-59 magnetite nanoparticles using the sol-gel method. The relevant findings have been published in the journal Applied Radiation and Isotopes. The sol-gel method is a chemical approach for preparing nanomaterials, with the core process involving the conversion of a liquid colloidal solution into a gel-like network...

2026-09-07

CNNC Headway's 13C-Urea Synthesis Control Method Patent Wins China Patent Excellence Award

On August 28, the China National Intellectual Property Administration officially released the decision on the 26th China Patent Award, and CNNC Headway's invention patent "A 13C-Urea Synthesis Control Method" won the China Patent Excellence Award. This patented technology addresses key technical bottlenecks in the batch production of carbon [13C]-urea API, establishing a set of synthesis control methods that provide technical support for the large-scale and stable production of the relevant API. The application of this technology helps enhance the self-sufficiency capability of the domestic urea [13C] breath diagnostic industry chain. CNNC Headway has long been deeply engaged in the breath diagnostic field, with sustained investment in innovative R&D, quality control, clinical adaptation, and industry chain layout...

2026-09-01

Russia Advances Radiopharmaceutical Development, Plans to Expand into Diagnostics and Treatment of Heart Disease and Other Conditions

Rosatom is developing radiopharmaceuticals for the diagnosis and treatment of neurodegenerative diseases, heart disease, and rheumatic conditions, further expanding the application of radionuclide technology in medicine. During the 13th International Technology Development Forum Technoprom-2026 held in Novosibirsk, Sergei Surov, Director of the Department of Radionuclide Products and Nuclear Medicine at Rosatom's Science Division, stated that the company is advancing the development of these drugs. Radiopharmaceuticals typically contain radioactive isotopes, i.e., radionuclides, and are currently used in medicine primarily for the diagnosis and treatment of various cancers. Surov noted that the new development directions mean...

2026-08-28

South Korea's Woojin Entech Patents Diagnostic Device for APR1400 Control Rod Position Transmitter

South Korea's Woojin Entech announced on August 27 that it has completed the development of a precision diagnostic device for the Control Rod Position Transmitter (RSPT) applicable to APR1400 units and has completed the relevant patent registration. The Control Rod Position Transmitter is used to measure the position of control rods within the reactor and transmit related signals to the control system, making it a critical component for reactor control and monitoring. The patented diagnostic device is primarily designed to accurately assess the status of the control rod control system and to pre-check multiple types of fault conditions before unit operation. According to the company, existing RSPT precision diagnostic systems require the installation of multiple cables during testing, making preparation work relatively complex...

2026-08-27

Five New Oncology Diagnostic and Treatment Devices at Bulgaria's ISUL Hospital Expected to Launch This Autumn

Queen Joanna - ISUL University Hospital in Bulgaria expects to begin operating five new devices for imaging diagnosis and treatment of oncological diseases starting early this autumn. The hospital stated that patients will be able to use these high-tech devices after the relevant licensing and approval procedures are completed. Source: Queen Joanna University Hospital - ISULThe newly added equipment is deployed in the imaging diagnostics department and the radiation oncology department. Among them, the radiation therapy department will be equipped with a TrueBeam v4.1 medical linear accelerator, primarily used for radiotherapy and radiosurgery. This device can deliver high-energy radiation to tumor tissue with greater precision, supporting high-precision dose planning to achieve the required therapeutic effect while minimizing radiation exposure to healthy tissues and organs surrounding the tumor.

2026-08-21

Organizational Diagnostic Assessment Completed at Russia's Smolensk Nuclear Power Plant

Russia's Smolensk Nuclear Power Plant has recently completed an organizational diagnostic assessment under a support mission of the WANO Moscow Centre. The assessment was carried out by a team of eight experts from the WANO Moscow Centre, Rosenergoatom, Beloyarsk Nuclear Power Plant, and Atomflot, among other organizations. Organizational diagnostics is a type of assessment that WANO has been conducting in recent years, focusing not on a single topic but on a comprehensive review of the plant from the organizational and operational perspective. The assessment covered areas including employee...

2026-08-21

LG Electronics Launches FDA-Approved 40-Inch Diagnostic Monitor for B2B Medical Imaging Market

LG Electronics announced on August 12 that it has launched a new 40-inch diagnostic monitor, the 40HT513D, targeting the business-to-business (B2B) medical display market. The product has received approval from the U.S. Food and Drug Administration (FDA) and is primarily intended for medical image interpretation. According to the company, the 40HT513D features a curved IPS black panel with a 21:9 aspect ratio and a resolution of 5120×2160, delivering approximately 11 million pixels. LG Electronics stated that this design consolidates image reading tasks that previously required three 3-megapixel monitors into a single screen. Physicians can simultaneously view and compare current and historical images from X-ray, CT scans, and MRI scans on the same display...

2026-08-12

Curium Acquires Belgium's Abscint, Expanding HER2-Targeted Gallium-68 PET Oncology Radiopharmaceutical Diagnostics Pipeline

On August 10, 2026, radiopharmaceutical company Curium announced the completion of its acquisition of Abscint SA, a Belgian clinical-stage radiopharmaceutical company. The transaction grants Curium global development, manufacturing, and commercialization rights to ABS-011, further expanding its oncology PET radiopharmaceutical diagnostics portfolio. ABS-011 is an investigational gallium-68-labeled positron emission tomography (PET) radiopharmaceutical diagnostic tracer targeting human epidermal growth factor receptor 2 (HER2). HER2 is an important biological target in multiple cancers, including breast cancer and gastric cancer. Based on available information, ABS-011 is designed to enable whole-body quantitative imaging of HER2 expression, and following further clinical development and regulatory approval, has the potential to provide more comprehensive HER2 status information for patient characterization and clinical assessment.

2026-08-11

Siemens Healthineers Introduces Next-Generation CT Technology in Vietnam, Bringing Imaging Diagnostics Closer to the Clinical Frontline

At the 27th Annual Scientific Meeting of the Vietnam Society of Radiology and Nuclear Medicine, Siemens Healthineers showcased two new advances in CT: the second-generation photon-counting CT system NAEOTOM Alpha Class, and the SOMATOM On.site mobile CT system, making its debut in Vietnam. These two product lines target high-precision imaging diagnostics and point-of-care bedside examinations respectively, reflecting how CT technology is moving beyond the mere pursuit of image quality toward greater clinical scenario adaptability and workflow optimization. The NAEOTOM Alpha Class is the next-generation product following the global launch of NAEOTOM Alpha in 2021. Photon-counting CT provides physicians with richer diagnostic information through higher detail visualization and multi-energy data acquisition...

2026-08-11

Grand Pharma's FAP-targeted diagnostic radiopharmaceutical GPN01530-2 receives FDA Fast Track designation

On August 9, 2026, Grand Pharmaceutical issued a voluntary announcement stating that its self-developed global innovative radionuclide drug conjugate GPN01530-2 has recently been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the diagnosis of solid tumors. Previously, the product had already been approved by the FDA to conduct Phase I/II clinical studies for the diagnosis of solid tumors. GPN01530-2 is a small-molecule radionuclide drug conjugate (RDC) targeting fibroblast activation protein (FAP). Data shows that FAP is not expressed or is lowly expressed in normal tissues, but is highly expressed in tumor-associated fibroblasts within the tumor microenvironment of various cancers, and is considered a novel specific target in the field of tumor diagnosis and treatment...

2026-08-10

American Fusion Inc Appoints Nuclear Diagnostics Expert as Strategic Advisor in Preparation for Texatron Testing

American Fusion Inc announced on August 3 that it has appointed Dr. Noah D'Amico as a strategic advisor to the company. The company stated that this move will strengthen its scientific, engineering, and advanced diagnostics team configuration, and support the next phase of its Texatron Fusion Engine testing program at Texas Tech University. After joining American Fusion Inc, Dr. D'Amico will continue his roles at Texas Tech University and BlankSlate Innovation, serving as Chief Operating Officer of BlankSlate Innov...

2026-08-04